| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8617591 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Jul, 2023
(2 months ago) | |
| US8246980 | UCB INC | Transdermal delivery system |
Nov, 2025
(2 years from now) | |
| US8246979 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Sep, 2027
(3 years from now) | |
| US10350174 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(7 years from now) | |
| US10130589 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(7 years from now) | |
| US9925150 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Mar, 2032
(8 years from now) | |
Neupro is owned by Ucb Inc.
Neupro contains Rotigotine.
Neupro has a total of 6 drug patents out of which 1 drug patent has expired.
Expired drug patents of Neupro are:
- US8617591
Neupro was authorised for market use on 09 May, 2007.
Neupro is available in film, extended release;transdermal dosage forms.
Neupro can be used as treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system; treatment of restless legs syndrome by application of claimed transdermal delivery system, a method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient.
The generics of Neupro are possible to be released after 01 March, 2032.
Drugs and Companies using ROTIGOTINE ingredient
Market Authorisation Date: 09 May, 2007
Treatment: A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient; Treatment of s...
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
NEUPRO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic